G01N 33/57555
Of the prostate
Official title: of the prostate
G01N33/57555 (Of the prostate) appears on 972 US grants and 2,273 published applications in this corpus.
Search patents in G01N- Granted patents
- 972
- Published applications
- 2,273
- Assignees
- 764
- Inventors
- 2,875
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 0 | 0 |
| 1997 | 9 | 0 |
| 1998 | 12 | 0 |
| 1999 | 15 | 0 |
| 2000 | 18 | 0 |
| 2001 | 19 | 4 |
| 2002 | 19 | 42 |
| 2003 | 15 | 536 |
| 2004 | 19 | 61 |
| 2005 | 11 | 68 |
| 2006 | 20 | 84 |
| 2007 | 49 | 69 |
| 2008 | 69 | 63 |
| 2009 | 33 | 65 |
| 2010 | 49 | 85 |
| 2011 | 46 | 78 |
| 2012 | 32 | 83 |
| 2013 | 33 | 95 |
| 2014 | 41 | 117 |
| 2015 | 43 | 106 |
| 2016 | 35 | 113 |
| 2017 | 53 | 90 |
| 2018 | 49 | 76 |
| 2019 | 51 | 78 |
| 2020 | 38 | 68 |
| 2021 | 44 | 74 |
| 2022 | 44 | 57 |
| 2023 | 29 | 43 |
| 2024 | 28 | 49 |
| 2025 | 24 | 42 |
| 2026 | 17 | 27 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Monoclonal antibody used for diagnosis and early onset of prostate cancer6 Oct 2026US 12,753,244 B2Taipei Medical University
- Molecular profiling of tumors6 Oct 2026US 12,754,193 B2Caris MPI, Inc.
- Compound, preparation method therefor, composition, kit and use thereof25 Aug 2026US 12,715,844 B2Signdo Biotechnology (Suzhou) Co., Ltd
- Anti-human neurotensin receptor 1 antibody and use thereof18 Aug 2026US 12,710,427 B2National Health Research Institutes
- Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer21 Jul 2026US 12,685,791 B2Memorial Sloan Kettering Cancer Center
- Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer1 Oct 2026US 2026/0295100 A1Memorial Sloan Kettering Cancer Center
- Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors1 Oct 2026US 2026/0297646 A1Cardiff Oncology, Inc.
- Methods for differentiating benign prostatic hyperplasia from prostate cancer24 Sep 2026US 2026/0287590 A1BPGbio, Inc.
- Molecular profiling of tumors3 Sep 2026US 2026/0259233 A1Caris MPI, Inc.
- Use of circulating tumor cell mitotic index in cancer stratification and diagnostics20 Aug 2026US 2026/0243767 A1Creatv MicroTech, Inc.
Most cited
By later US patents
- Detecting, localizing, and targeting internal sites in vivo using optical contrast agents209US 6,167,297 A2000
- Detecting, localizing, and targeting internal sites in vivo using optical contrast agents202US 6,246,901 B12001
- Prediction of prostate cancer progression by analysis of selected predictive parameters195US 6,025,128 ACytodiagnostics, Inc. · 2000
- Modified PSMA ligands and uses related thereto119US 6,875,886 B2Beth Israel Deaconess Medical Center, Inc. · 2005
- Biomarkers and targets for diagnosis, prognosis and management of prostate disease113US 5,972,615 AUrocor, Inc. · 1999